• 1
    Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758760.
  • 2
    Kupiec-Weglinski JW. Graft rejection in sensitized recipients. Ann Transplant 1996; 1: 3440.
  • 3
    Kanmaz T, Fechner JJ, Jr., Torrealba J et al. Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004; 77: 914920.
  • 4
    Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665673.
  • 5
    Kriaa F, Laurian Y, Hiesse C, Tchernia G, Charpentier B. Five years' experience at one centre with protein A immunoadsorption in patients with deleterious allo/autoantibodies (anti-HLA antibodies, autoimmune bleeding disorders) and post-transplant patients relapsing with focal glomerular sclerosis. Nephrol Dial Transplant 1995; 10(6 Suppl): 108110.
  • 6
    Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 1012.
  • 7
    Ross CN, Gaskin G, Gregor-Macgregor S et al. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation 1993; 55: 785789.
  • 8
    Rocha PN, Butterly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 14901495.
  • 9
    Sonnenday CJ, Ratner LE, Zachary AA et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34: 16141616.
  • 10
    Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 10331041.
  • 11
    Takeda A, Uchida K, Haba T et al. Acute humoral rejection of kidney allografts in patients with a positive flow cytometry crossmatch (FCXM). Clin Transplant 2000; 14(3 Suppl): 1520.
  • 12
    Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 1990; 16: 423431.
  • 13
    Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553562.
  • 14
    Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 6873.
  • 15
    Platt JL, Saadi S. The role of complement in transplantation. Mol Immunol 1999; 36: 965971.
  • 16
    Halloran PF. The clinical importance of alloantibody-mediated rejection. Am J Transplant 2003; 3: 639640.
  • 17
    Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4 d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 22082214.
  • 18
    Pratt JR, Hibbs MJ, Laver AJ, Smith RA, Sacks SH. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996; 149: 20552066.
  • 19
    Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 1991; 50: 350355.
  • 20
    Baldwin WM, 3rd, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F. Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation 1995; 59: 797808.
  • 21
    Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582587.
  • 22
    Brauer RB, Baldwin WM, 3rd, Ibrahim S, Sanfilippo F. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation 1995; 59: 288293.
  • 23
    Kroshus TJ, Rollins SA, Dalmasso AP et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60: 11941202.
  • 24
    Wang H, Rollins SA, Gao Z et al. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation 1999; 68: 16431651.
  • 25
    Wang H, Jiang J, Liu W et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 2005; 79: 11211127.
  • 26
    Wang H, Arp J, Liu W et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007; 179: 44514463.
  • 27
    Yang H, Chen G, Kanai N et al. Monotherapy with LF 15–0195, an analogue of 15-deoxyspergualin, significantly prolongs renal allograft survival in monkeys. Transplantation 2003; 75: 11661171.
  • 28
    Thomas JM, Contreras JL, Jiang XL et al. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999; 68: 16601673.
  • 29
    Lan HY, Zarama M, Nikolic-Paterson DJ, Kerr PG, Atkins RC. Suppression of experimental crescentic glomerulonephritis by deoxyspergualin. J Am Soc Nephrol 1993; 3: 17651774.
  • 30
    Tesch GH, Hill PA, Wei M, Nikolic-Paterson DJ, Dutartre P, Atkins RC. LF15–0195 prevents the induction and inhibits the progression of rat anti-GBM disease. Kidney Int 2001; 60: 13541365.
  • 31
    Nikolic-Paterson DJ, Kerr PG, Lan HY, Tesch GH, Atkins RC. Deoxyspergualin: A new immunosuppressive drug for the treatment of auto-immune disease. Nephron 1995; 70: 391396.
  • 32
    Fujii H, Takada T, Nemoto K et al. Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot (Tokyo) 1990; 43: 213219.
  • 33
    Josien R, Pannetier C, Douillard P et al. Graft-infiltrating T helper cells, CD45RC phenotype, and Th1/Th2-related cytokines in donor-specific transfusion-induced tolerance in adult rats. Transplantation 1995; 60: 11311139.
  • 34
    Cuturi MC, Josien R, Cantarovich D et al. Decreased anti-donor major histocompatibility complex class I and increased class II alloantibody response in allograft tolerance in adult rats. Eur J Immunol 1994; 24: 16271631.
  • 35
    Tepper MA, Nadler SG, Esselstyn JM, Sterbenz KG. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J Immunol 1995; 155: 24272436.
  • 36
    Wang B, Benoist C, Mathis D. The immunosuppressant 15-deoxyspergualin [correction of 1,5-deoxyspergualin] reveals commonality between preT and preB cell differentiation. J Exp Med 1996; 183: 24272436.
  • 37
    Hoeger PH, Tepper MA, Faith A, Higgins JA, Lamb JR, Geha RS. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol 1994; 153: 39083916.
  • 38
    Nosaka C, Kunimoto S, Atsumi S, Takeuchi T. Inhibition of nitric oxide synthase induction by 15-deoxyspergualin in a cultured macrophage cell line, J774 A.1 [correction of J744 A.1] activated with IFN-gamma and LPS. J Antibiot (Tokyo) 1999; 52: 297304.
  • 39
    Takasu S, Sakagami K, Morisaki F et al. Immunosuppressive mechanism of 15-deoxyspergualin on sinusoidal lining cells in swine liver transplantation: Suppression of MHC class II antigens and interleukin-1 production. J Surg Res 1991; 51: 165169.
  • 40
    Waaga AM, Ulrichs K, Krzymanski M et al. The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC-antigen expression and interleukin-1 production in the early phase of rat allograft responses. Transplant Proc 1990; 22: 16131614.
  • 41
    Yang J, Bernier SM, Ichim TE et al. LF15–0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol 2003; 74: 438447.
  • 42
    Olfert ED, Cross BM, McWilliam AA. Responsibility for the care and use of experimental animals. In: OlfertED, CrossBM, McWilliamAA (eds). Guide to the Care and Use of Experimental Animals (Vol1). Ottawa : Association of Universities and Colleges of Canada, 1993; 114.
  • 43
    Junge W, Wilke B, Halabi A, Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 2004; 344: 137148.
  • 44
    Binder J, Lehmann M, Graser E et al. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 1996; 61: 804811.
  • 45
    Onodera K, Lehmann M, Akalin E, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Induction of “infectious” tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol 1996; 157: 19441950.
  • 46
    Arp J, LeVatte M, Rowe J et al. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: Expression of gp46 by the vaccinia virus/T7 polymerase system. J Virol 1996; 70: 73497359.
  • 47
    Bach FH, Ferran C, Hechenleitner P et al. Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196204.
  • 48
    Nickerson P, Steurer W, Steiger J, Zheng X, Steele AW, Strom TB. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994; 6: 757764.
  • 49
    Janeway C. Immunobiology: The Immune System in Health and Disease. 6th Ed. New York; London : Garland Science, 2005.
  • 50
    Ho S, Clipstone N, Timmermann L et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80(3 Pt 2): S40S45.
  • 51
    Marchman W, Araneda D, DeMasi R et al. Prolongation of xenograft survival after combination therapy with 15-deoxyspergualin and total-lymphoid irradiation in the hamster-to-rat cardiac xenograft model. Transplantation 1992; 53: 3034.
  • 52
    Wang H, Hosiawa KA, Garcia B et al. Attenuation of acute xenograft rejection by short-term treatment with LF15–0195 and monoclonal antibody against CD45RB in a rat-to-mouse cardiac transplantation model. Transplantation 2003; 75: 14751481.
  • 53
    Wang H, Hosiawa KA, Garcia B et al. Treatment with a short course of LF 15–0195 and continuous cyclosporin A attenuates acute xenograft rejection in a rat-to-mouse cardiac transplantation model. Xenotransplantation 2003; 10: 325336.
  • 54
    Chen G, Sun H, Yang H et al. The role of anti-non-Gal antibodies in the development of acute humoral xenograft rejection of hDAF transgenic porcine kidneys in baboons receiving anti-Gal antibody neutralization therapy. Transplantation 2006; 81: 273283.
  • 55
    Reichenspurner H, Human PA, Boehm DH et al. Optimalization of immunosuppression after xenogeneic heart transplantation in primates. J Heart Transplant 1989; 8: 200207; discussion 207–208.
  • 56
    Zhou D, O'Brien C, Shum J et al. LF 15–0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model. Transplantation 2003; 76: 644650.
  • 57
    Min WP, Zhou D, Ichim TE et al. Synergistic tolerance induced by LF15–0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation 2003; 75: 11601165.
  • 58
    Chiffoleau E, Beriou G, Dutartre P, Usal C, Soulillou JP, Cuturi MC. Induction of donor-specific allograft tolerance by short-term treatment with LF15–0195 after transplantation. Evidence for a direct effect on T-cell differentiation. Am J Transplant 2002; 2: 745757.
  • 59
    Chiffoleau E, Beriou G, Dutartre P, Usal C, Soulillou JP, Cuturi MC. Role for thymic and splenic regulatory CD4+ T cells induced by donor dendritic cells in allograft tolerance by LF15–0195 treatment. J Immunol 2002; 168: 50585069.
  • 60
    Heslan JM, Beriou G, Le Luduec JB et al. Accumulation of T cells with potent regulatory properties and restricted Vbeta7-TCR rearrangements in tolerated allografts. Transplantation 2005; 80: 14761484.
  • 61
    Thebault P, Condamine T, Heslan M et al. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 2007; 7: 24722482.
  • 62
    Takeuchi I, Chikaraishi T, Seki T, Kanagawa K, Koyanagi T. Immunological analysis of rat renal transplant recipients exhibiting long-term survival following treatment with 15-deoxyspergualin in the early postoperative phase. Int J Urol 1998; 5: 476481.
  • 63
    Liszewski KM. In: PaulWE, (ed). Fundamental Immunology. New York : Raven, 1993; pp. 917939.
  • 64
    Jose PJ, Forrest MJ, Williams TJ. Detection of the complement fragment C5 a in inflammatory exudates from the rabbit peritoneal cavity using radioimmunoassay. J Exp Med 1983; 158: 21772182.
  • 65
    Kirschfink M. Targeting complement in therapy. Immunol Rev 2001; 180: 177189.
  • 66
    Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 18071814.
  • 67
    Papadimitriou JC, Ramm LE, Drachenberg CB, Trump BF, Shin ML. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J Immunol 1991; 147: 212217.
  • 68
    Baldwin WM, 3rd, Larsen CP, Fairchild RL. Innate immune responses to transplants: A significant variable with cadaver donors. Immunity 2001; 14: 369376.
  • 69
    Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today 1991; 12: 338342.
  • 70
    Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996; 149: 953961.
  • 71
    Qian Z, Wasowska BA, Behrens E et al. C6 produced by macrophages contributes to cardiac allograft rejection. Am J Pathol 1999; 155: 12931302.
  • 72
    Hepburn NJ, Williams AS, Nunn MA et al. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 2007; 282: 82928299.
  • 73
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 27152729.
  • 74
    Brauer RB, Baldwin WM, 3rd, Daha MR, Pruitt SK, Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151: 72407248.
  • 75
    Cochrane CG, Muller-Eberhard HJ, Aikin BS. Depletion of plasma complement in vivo by a protein of cobra venom: Its effect on various immunologic reactions. J Immunol 1970; 105: 5569.
  • 76
    Tavakoli R, Michel A, Cardoso J et al. Prolonged survival of guinea pig-to-rat heart xenografts using repeated low doses of cobra venom factor. Transplant Proc 1993; 25(1 Pt 1): 407409.
  • 77
    Baldwin WM, Ota H, Rodriguez ER. Complement in transplant rejection: Diagnostic and mechanistic considerations. Springer Semin Immunopathol 2003; 25: 181197.
  • 78
    Hayashi S, Ito M, Yokoyama I, Uchida K, Takagi H. Effectiveness of combination therapy using cobra venom factor, splenectomy, and deoxyspergualin in guinea pig to rat cardiac xenografts. Transplant Proc 1993; 25(1 Pt 1): 405406.
  • 79
    Pruitt SK, Baldwin WM, 3rd, Marsh HC, Jr., Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991; 52: 868873.
  • 80
    Holzknecht ZE, Coombes S, Blocher BA et al. Immune complex formation after xenotransplantation: Evidence of type III as well as type II immune reactions provide clues to pathophysiology. Am J Pathol 2001; 158: 627637.
  • 81
    Lau CL, Cantu E, 3rd, Gonzalez-Stawinski GV et al. The role of antibodies and von Willebrand factor in discordant pulmonary xenotransplantation. Am J Transplant 2003; 3: 10651075.
  • 82
    Pratt JR, Hibbs MJ, Laver AJ, Smith RA, Sacks SH. Allograft immune response with sCR1 intervention. Transpl Immunol 1996; 4: 7275.
  • 83
    Koch CA, Khalpey ZI, Platt JL. Accommodation: Preventing injury in transplantation and disease. J Immunol 2004; 172: 51435148.
  • 84
    Fan X, Ang A, Pollock-Barziv SM et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004; 10: 12271233.
  • 85
    Bach FH, Hancock WW, Ferran C. Protective genes expressed in endothelial cells: A regulatory response to injury. Immunol Today 1997; 18: 483486.
  • 86
    Mohiuddin MM, Ogawa H, Yin DP, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation 2003; 75: 258262.
  • 87
    Ishida H, Tanabe K, Ishizuka T et al. The mechanism responsible for accommodation after living-related kidney transplantations across the blood barrier. Transpl Int 2005; 18: 716720.
  • 88
    Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807817.
  • 89
    Leatherbarrow RJ, Dwek RA. Binding of complement subcomponent C1q to mouse IgG1, IgG2 a and IgG2b: A novel C1q binding assay. Mol Immunol 1984; 21: 321327.
  • 90
    Yin D, Zeng H, Ma L et al. Cutting Edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts. J Immunol 2004; 172: 72357238.
  • 91
    Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM, 3rd, Wasowska BA. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant 2004; 4: 326334.
  • 92
    Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 12331243.
  • 93
    Hillmen P, Muus P, Duhrsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 41234128.
  • 94
    Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552559.